CompletedPhase 1NCT02323139
A Study of LDE255 in Combination With Azacitidine for High Risk Myelodysplastic Syndrome Patients
Studying Myelodysplastic neoplasm with increased blasts
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Groupe Francophone des Myelodysplasies
- Principal Investigator
- Thomas PREBET, MDPaoli Calmettes institute
- Intervention
- Azacitidine and LDE255(drug)
- Enrollment
- 23 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2015 – 2018
Study locations (24)
- CHU d'Amiens, Amiens, France
- CHU d'Angers, Angers, France
- CH Henri Duffaut, Avignon, France
- CH de la Côte Basque, Bayonne, France
- Hôpital Avicenne, Bobigny, France
- Hôpital Henri Mondor, Créteil, France
- CHU de Grenoble, Grenoble, France
- CH Le Mans, Le Mans, France
- IPC-Unité d'Hématologie 3, Marseille, France
- Centre Hospitalier de Meaux, Meaux, France
- CHU de Montpellier, Montpellier, France
- Hôpital Hôtel Dieu, Nantes, France
- Centre Antoine Lacassagne, Nice, France
- Hôpital Archet 1, Nice, France
- CHU de Nîmes, Nîmes, France
- +9 more locations on ClinicalTrials.gov
Collaborators
Novartis
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02323139 on ClinicalTrials.govOther trials for Myelodysplastic neoplasm with increased blasts
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT06616636A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)M.D. Anderson Cancer Center
- RECRUITINGPHASE1NCT06138587Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell TransplantationDana-Farber Cancer Institute
- ACTIVE NOT RECRUITINGPHASE2NCT04994808Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid LeukemiaFred Hutchinson Cancer Center
- RECRUITINGPHASE2NCT04741945Repurposing Metformin As a Leukemia-preventive Drug in CCUS and LR-MDSKirsten Grønbæk
- RECRUITINGPHASE1NCT04275518A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.Ascentage Pharma Group Inc.
- ACTIVE NOT RECRUITINGPHASE1NCT03974217Talazoparib for Cohesin-Mutated AML and MDS With Excess BlastsDana-Farber Cancer Institute
- ACTIVE NOT RECRUITINGPHASE3NCT03682536A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA NaïveCelgene
- RECRUITINGPHASE1, PHASE2NCT03471260Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic MalignanciesM.D. Anderson Cancer Center
See all trials for Myelodysplastic neoplasm with increased blasts →